stoxline Quote Chart Rank Option Currency Glossary
Inovio Pharmaceuticals, Inc. (INO)
11.03  -0.73 (-6.21%)    04-12 16:00
Open: 11.67
High: 11.8999
Volume: 261,284
Pre. Close: 11.76
Low: 10.82
Market Cap: 258(M)
Technical analysis
2024-04-12 4:50:08 PM
Short term     
Mid term     
Targets 6-month :  14.64 1-year :  17.22
Resists First :  12.54 Second :  14.75
Pivot price 12.14
Supports First :  8.97 Second :  7.46
MAs MA(5) :  11.45 MA(20) :  11.8
MA(100) :  7.89 MA(250) :  6.88
MACD MACD :  0.4 Signal :  0.7
%K %D K(14,3) :  19.6 D(3) :  25.3
RSI RSI(14): 48.4
52-week High :  14.75 Low :  3.83
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ INO ] has closed above bottom band by 12.1%. Bollinger Bands are 15.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.93 - 11.99 11.99 - 12.03
Low: 10.67 - 10.74 10.74 - 10.8
Close: 10.92 - 11.04 11.04 - 11.13
Company Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Headline News

Fri, 12 Apr 2024
Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100 - Yahoo Movies Canada

Fri, 12 Apr 2024
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Thu, 11 Apr 2024
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Wed, 10 Apr 2024
Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Tue, 09 Apr 2024
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Mon, 08 Apr 2024
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 23 (M)
Held by Insiders 2.299e+007 (%)
Held by Institutions 1.6 (%)
Shares Short 1,740 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.3066e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -26 %
Return on Assets (ttm) 686.2 %
Return on Equity (ttm) -32.2 %
Qtrly Rev. Growth 832010 %
Gross Profit (p.s.) -15.81
Sales Per Share -71.03
EBITDA (p.s.) 0
Qtrly Earnings Growth -6.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -124 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales -0.16
Price to Cash Flow 2.39
Stock Dividends
Dividend 0
Forward Dividend 2.06e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android